We are live on
!
Find out more
BLAM
Bourne Lent Asset Management Portfolio holdings
AUM
$272M
1-Year Est. Return
30.95%
This Fund
S&P 500
This Quarter
Est. Return
+12.22%
1 Year Est. Return
+30.95%
3 Year Est. Return
+75.66%
5 Year Est. Return
+99.24%
10 Year Est. Return
+591.34%
AUM
$212M
AUM Growth
+$3.81M
(+1.8%)
Cap. Flow
-$14.4M
Cap. Flow
% of AUM
-6.8%
Top 10 Holdings %
Top 10 Hldgs %
75.52%
Holding
61
New
5
Increased
12
Reduced
13
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$23.8M |
| 2 |
Enbridge
ENB
|
+$503K |
| 3 |
L3Harris
LHX
|
+$501K |
| 4 |
Amazon
AMZN
|
+$443K |
| 5 |
Illumina
ILMN
|
+$405K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$41.3M |
| 2 |
Idexx Laboratories
IDXX
|
+$174K |
| 3 |
GE Aerospace
GE
|
+$152K |
| 4 |
Verizon
VZ
|
+$124K |
| 5 |
Pfizer
PFE
|
+$119K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 40.99% |
| 2 | Healthcare | 33.84% |
| 3 | Communication Services | 10.02% |
| 4 | Consumer Discretionary | 4.46% |
| 5 | Industrials | 3.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Adobe
ADBE
$89.5B
| $31.8M | 14.99% |
96,465
| – | – |
|
|
2
Bristol-Myers Squibb
BMY
$127B
| $27.1M | 12.78% |
422,735
+415,315
| +5,597% | +$23.8M |
|
|
3
Idexx Laboratories
IDXX
$42.9B
| $23.6M | 11.13% |
90,522
-660
| -0.7% | -$174K |
|
4
Microsoft
MSFT
$2.84T
| $18.7M | 8.81% |
118,662
-72
| -0.1% | -$10.6K |
|
5
Apple
AAPL
$4.89T
| $15.1M | 7.09% |
205,084
-1,148
| -0.6% | -$73.9K |
|
6
Intuitive Surgical
ISRG
$121B
| $10.1M | 4.76% |
51,309
| – | – |
|
7
Alphabet (Google) Class C
GOOG
$3.9T
| $9.43M | 4.44% |
141,080
-160
| -0.1% | -$10.3K |
|
|
8
Alphabet (Google) Class A
GOOGL
$3.91T
| $8.78M | 4.14% |
131,120
| – | – |
|
9
Paychex
PAYX
$40.4B
| $7.83M | 3.69% |
92,095
-200
| -0.2% | -$16.9K |
|
10
Cisco
CSCO
$450B
| $7.83M | 3.69% |
163,264
+2,918
| +2% | +$136K |
|
11
Booking.com
BKNG
$138B
| $4.42M | 2.08% |
53,750
| – | – |
|
|
12
Amazon
AMZN
$2.5T
| $4.07M | 1.92% |
44,100
+5,000
| +13% | +$443K |
|
13
Qualcomm
QCOM
$176B
| $3.81M | 1.8% |
43,203
| – | – |
|
14
United Parcel Service
UPS
$97.6B
| $3.24M | 1.53% |
27,694
+200
| +0.7% | +$23.7K |
|
|
15
Enbridge
ENB
$124B
| $2.69M | 1.27% |
67,697
+13,475
| +25% | +$503K |
|
16
Johnson & Johnson
JNJ
$635B
| $2.43M | 1.14% |
16,651
| – | – |
|
17
T. Rowe Price
TROW
$25B
| $2.43M | 1.14% |
19,910
-50
| -0.3% | -$5.9K |
|
18
Pacific Biosciences
PACB
$422M
| $2.27M | 1.07% |
441,650
| – | – |
|
19
AT&T
T
$165B
| $2.26M | 1.06% |
76,617
+13,638
| +22% | +$394K |
|
20
Tompkins Financial
TMP
$1.45B
| $2.07M | 0.98% |
22,650
+2,000
| +10% | +$173K |
|
21
Quanta Services
PWR
$93.9B
| $1.86M | 0.88% |
45,775
+25
| +0.1% | +$1.02K |
|
22
Nutrien
NTR
$32.7B
| $1.85M | 0.87% |
38,712
-80
| -0.2% | -$3.87K |
|
23
Amgen
AMGN
$203B
| $1.25M | 0.59% |
5,187
+300
| +6% | +$66.1K |
|
24
Visa
V
$677B
| $1.22M | 0.58% |
6,500
| – | – |
|
|
25
Pfizer
PFE
$140B
| $1.1M | 0.52% |
29,490
-3,352
| -10% | -$119K |
|
Similar funds
SC
SC
AGP
SFPG
TP
S
SS
LAM
Bourne Lent Asset Management's Q4 2019 Portfolio in Review
As of Q4 2019, Bourne Lent Asset Management held 61 positions worth $212M, up 1.8% from $209M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Bourne Lent Asset Management withdrew a net $14.4M in Q4 2019, closing 1 position and reducing 13 holdings. Its most notable exit was Celgene Corp, an estimated $41.3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 36% a quarter earlier, followed by Healthcare and Communication Services.
Against the trend, Bourne Lent Asset Management opened a new position in Gilead Sciences worth $354K.
- Bourne Lent Asset Management's largest Q4 2019 buy was Gilead Sciences: 5,455 shares worth $354K.
- Bourne Lent Asset Management added most to Bristol-Myers Squibb in Q4 2019, an estimated $23.8M increase.
- Bourne Lent Asset Management's biggest Q4 2019 reduction was Idexx Laboratories, cutting an estimated $174K.
- Bourne Lent Asset Management fully exited Celgene Corp in Q4 2019, selling an estimated $41.3M.
- Bourne Lent Asset Management's ten largest holdings make up 76% of its $212M portfolio in Q4 2019.
- Bourne Lent Asset Management opened 5 new positions and closed 1 in Q4 2019.
- Bourne Lent Asset Management's portfolio value rose 1.8% quarter-over-quarter to $212M.
Based on Bourne Lent Asset Management's 13F filing for Q4 2019, filed 24 Jan 2020.